摘要
目的:探讨西妥昔单抗与NK、T混合淋巴细胞联合应用对肺癌细胞的体外抑制作用。方法:体外诱导和扩增外周血淋巴细胞,流式细胞仪检测扩增后细胞表型。CCK-8法检测西妥昔单抗与NKTm细胞以不同时间点联合应用对A549细胞的抑制率,采用金氏公式计算增效Q值,评价合用的效应强度是否优于单用。结果:西妥昔单抗与NK、T混合淋巴细胞联合应用组的抑制率高于两者单独应用组(P<0.01),联合应用具有协同效应(Q>1.15),西妥昔单抗应用后18小时再给予NK、T混合淋巴细胞组的Q值最高(Q=1.31)。结论:西妥昔单抗与NK、T混合淋巴细胞联合应用对A549细胞的抑制具有协同效应。
Objective：To investigate the inhibition effect of Cetuximab combined with mixture of NK and T lymphocytes（NKTm cells）against lung cancer cells.Methods：Inducing and amplifying the lymphocytes from peripheral blood and detect the lymphocyte phenotype by flow cytometry.The inhibited rates of A.549 cells in Cetuximab group,NKTm cells group and the combinition group were determined by CCK-8 assay.The formula of Jin Zhenjun was used to evaluate whether the effect of combination is better than alone.Results：The inhibited rate of A549 cells in combinition group was higher than Cetuximab group and NKTm cells group （P ＜ 0.01）.Combined use of Cetuximab and NKTm cells had synergistic effect （Q ＞ 1.15）.The best synergistic effect was observed when NKTm cells administered 18 hour after the use of Cetuximab （Q =1.31）.Conclusion：Combined treatment of Cetuximab and NKTm cells had synergistic effect against A549 cells.
出处
《现代肿瘤医学》
CAS
2013年第11期2402-2404,共3页
Journal of Modern Oncology
基金
国家科技部科研支撑计划项目(编号:2009BAI86B05)
